Publications by authors named "Tivadar S"
Article Synopsis
- - Psoriasis vulgaris is a long-lasting skin disease caused by an immune response, and biologic therapies have been common treatments for moderate to severe cases for over a decade.
- - Initially, treatments targeted TNF-α; however, more advanced biologics targeting different interleukins like IL-17 and IL-23 have since been developed.
- - A 49-year-old woman with diabetes experienced a severe adverse reaction (palmoplantar pustular reaction) from the biologic adalimumab, leading to a successful switch to ixekizumab after stopping the original treatment.
Tumor glycans constitute attractive targets for therapeutic antibodies. The sialylated glycocalyx plays a prominent role in cancer progression and immune evasion. Here, we describe the characterization of the mAb, FG129, which targets tumor-associated sialylated glycan, and demonstrate its potential for multimodal cancer therapy.
View Article and Find Full Text PDF